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Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in developed
countries. NAFLD encompasses a spectrum of diseases, ranging from hepatic steatosis to non-alcoholic steatohepatitis
(NASH), cirrhosis, and liver failure. The etiology of NAFLD remains unclear but is thought to relate to increased fatty
acid flux within the liver that results in toxic fatty acid metabolite production. One source of increased fatty acid flux is
fructose/sucrose-induced hepatic lipogenesis. Current treatment for NAFLD encompasses dietary modifications. However,
little scientific evidence exists on which to base many dietary recommendations, especially the intake of different types
of carbohydrates and fats. We hypothesized that lipid mixtures of unsaturated fatty acids would inhibit lipogenesis and
subsequent hepatic steatosis induced by high carbohydrate diets. The aim of this study was to examine the effects of
different complex mixtures of fatty acids upon the development of fructose/sucrose-induced hepatic steatosis.
Methods: C57BL/6 mice were randomized to normocaloric chow-based diets that varied in the type of carbohydrate
(starch, sucrose, fructose). Animals in each carbohydrate group were further randomized to diets that varied in lipid
type (no additional lipid, soybean oil, fish oil, olive/soybean oil, macadamia nut oil). These oils were chosen based upon
their content of omega-6 polyunsaturated fatty acids, omega-3 polyunsaturated fatty acids, omega-9 monounsaturated
fatty acids, or omega-7 monounsaturated fatty acids. Fatty acid flux in the liver was determine by assessing hepatic
lipid content (steatosis). We also assessed fatty acid levels in the plasma and liver of the animals, hepatic lipogenesis
activity, hepatic stearoyl-CoA-1 desaturase activity, and hepatic elongase activity.
Results: Animals consumed similar amounts of the diets and maintained normal body weights throughout the study.
Both sucrose and fructose induced hepatic lipogenesis and steatosis, with fructose being more potent. All mixed lipids
similarly inhibited steatosis, limiting lipid content to levels found in the control (starch) animals. Lipogenesis and
stearoyl-CoA-1 desaturase activity were increased in the sucrose and fructose groups. Levels of these enzymatic
processes remained at baseline in all of the lipid groups.
Conclusion: This is the first study to compare various complex lipid mixtures, based upon dietary oils with different
types of long-chain fatty acids, upon development of sucrose/fructose-induced steatosis. Both carbohydrate source
and lipid content appear important for the modulation of steatosis. Moderate intake of complex lipids with high
unsaturated to saturated fatty acid ratios inhibited both lipogenesis and steatosis.
Keywords: Hepatic steatosis, Non-alcoholic fatty liver disease (NAFLD), Nonalcoholic steatohepatitis (NASH), Parenteral-
nutrition-associated liver disease (PNALD), Soybean oil, Olive oil, Macadamia nut oil, Fish oil, Lipid emulsion, Fatty acids,
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Background
Non-alcoholic fatty liver disease (NAFLD) is one of
the most common forms of chronic liver disease in
developed countries, affecting 20-60 % of the population
[1–3]. NAFLD encompasses a spectrum of diseases that
includes steatosis, nonalcoholic steatohepatitis (NASH),
fibrosis, cirrhosis, liver failure, and hepatocellular carcin-
oma [1, 3, 4]. Development of steatosis and progression of
steatosis to NASH and cirrhosis has been postulated to
involve two insults [5, 6]. The first insult results in steato-
sis due to alterations in hepatic uptake, synthesis, metab-
olism, and secretion of fatty acids. The accumulation of
lipids within hepatocytes predisposes the liver to a second
insult that results in inflammation and oxidative injury.
The net result is hepatic damage that progresses to fibrosis
and liver failure. However, it is now believed that a more
complex process is involved [4, 7, 8], which encompasses
multiple parallel pathways that result in tissue injury and
progression to fibrosis. Lipotoxicity represents one of the
major metabolic pathways underlying hepatocyte dysfunc-
tion leading to disease progression [4, 7, 8]. It is postulated
that excess free fatty acid (FFA) traffic (from diet, de novo
lipogenesis, adipose lipolysis, impaired lipid oxidation)
within hepatocytes that accompanies the development of
steatosis leads to the generation of toxic lipid metabolites
(i.e., acyl-CoA, lysophosphatidylcholine, ceramides, phos-
phatidic acid), which increase oxidative stress and inflam-
mation (i.e., induction of NFκB, IL-6, IL-1, TNF-alpha),
resulting in hepatocyte injury that leads to cirrhosis and
liver failure [7, 9]. Increased fatty acid flux and triglyceride
formation results largely from an increased supply of fatty
acids (i.e., from lipolysis and diet) and de novo lipogenesis
[10–12]. Both processes are increased in patients with
NAFLD [10–12] and play important roles in lipid accu-
mulation. Inhibition of hepatic steatosis (i.e., free fatty acid
flux) has been shown to prevent progression of steatosis
to NASH/cirrhosis [13–15].
The pathophysiologic role of diet in the development
and progression of NAFLD is unclear. High caloric in-
take (overfeeding), high fat intake (especially saturated
fatty acids), and high intake of simple sugars are all
implicated in the pathogenesis of NAFLD. All of these
dietary factors likely interact with genetic factors and
result in hepatic lipid accumulation and cellular injury.
Recent concern regarding NAFLD pathogenesis focuses
upon high dietary intake of simple sugars [16–18], with
fructose and sucrose being the most important sugars.
Fructose/sucrose are used as sweeteners in many proc-
essed foods and beverages (especially soft drinks) [17, 18].
Fructose is known to stimulate de novo lipogenesis and
inflammation/oxidation within the liver [18]. Although
evidence is inconclusive, there is a growing belief that
high fructose consumption is an important contributor
to NAFLD [10, 17, 19, 20].
In addition to fructose/sucrose consumption, high fat
intake and high saturated fatty acid intake [21, 22] have
been implicated in the pathogenesis of NAFLD. In con-
trast to saturated fatty acids, high intake of polyunsatur-
ated fatty acids reportedly inhibit NAFLD development
[13, 23–25]. Polyunsaturated fatty acids also inhibit de
novo lipogenesis [25–28]. In addition, fatty acids modu-
late inflammation, oxidation (including lipid peroxida-
tion), immune reactions, endoplasmic reticulum stress,
collagen formation, apoptosis and necrosis, endothelial
integrity, and insulin resistance [4, 7]. Thus, the types of
fatty acids that accumulate in hepatocytes during devel-
opment of steatosis (from both endogenous and exogen-
ous sources) are likely to modulate the development of
NAFLD and its progression to NASH/cirrhosis.
We hypothesized that fructose interacts with lipid in the
pathogenesis of NAFLD and that unsaturated fatty acids
(i.e. oleic acid, palmitoleic acid, linoleic acid, docosahexae-
noic acid, eicosapentaenoic acid) inhibit the development
of steatosis. The goal of this study was to examine the
effects of complex mixtures of fatty acids based upon dif-
ferent dietary oils (that reflects the types of lipids ingested
by patients) upon the development of fructose/sucrose-
induced hepatic steatosis. We compared the effects of
mixtures of dietary lipids that varied in the quantities
of omega-6 polyunsaturated fatty acids (soybean oil),
omega-3 polyunsaturated fatty acids (fish oil), omega-9
monounsaturated fatty acids (olive oil, macadamia nut
oil), and omega-7 monounsaturated fatty acids (macada-
mia nut oil) upon hepatic lipid content. This is the first
study to compare the effects of these different mixed
lipids, varying in unsaturated fatty acid type (i.e. oleic acid,
palmitoleic acid, linoleic acid, docosahexaenoic acid,
eicosapentaenoic acid), upon development of fructose/
sucrose-induced hepatic steatosis.
Methods
Animals, study diets and lipid emulsions
C57BL/6 male mice, 6 weeks old, were housed under
controlled temperature and humidity in the Methodist
Research Institute’s Animal Care Facility, with a 12-hour
light-dark cycle, and fed the study diets and water ad
libitum. After 3 days of acclimation to the facility (receiv-
ing standard chow diets), mice were fed for the next 3 days
with a low fat diet based on the AIN-76A rodent diet
containing starch (corn starch and maltodextrin), sucrose,
or fructose as the carbohydrate source. The starch diet
was identical to the normal chow diet except for the
reduced fat content. The diets provided similar quantities
of carbohydrate (665 g/kg), protein (casein; 200 g/kg), and
lipid (soybean oil; 5 g/kg). A small amount of soybean oil
was added to the diets to meet essential fatty acid
requirements of the animals. The diets were supple-
mented with recommended amounts of DL-methionine
Siddiqui et al. Nutrition & Metabolism  (2015) 12:41 Page 2 of 14
(3 g/kg), vitamins, and minerals. In preliminary studies
(not published), we established that the sucrose and fruc-
tose diets induced hepatic steatosis in the animals. The
study lipids were provided in the form of a lipid emulsion
and fed to animals for days 3-8 of the study. In previous
studies, we found that supplying the oils as an emulsion
improved absorption and none of the animals developed
loose stools or diarrhea.
In this study, animals were randomly divided into three
groups that received starch (normal diet), sucrose, or fruc-
tose as the carbohydrate source; each carbohydrate group
was further randomized into five groups that received no
additional lipid, or one of the four lipid emulsions for a
total of 15 groups of 5 animals per group. Lipid emulsions
were administered to animals daily (day 3-8) by gavage
and supplied 90 mg/day of lipid to the animals. Lipid
emulsion triglyceride concentrations are reported as per-
cent (%) which reflects weight/volume (g/dL) of lipid.
Lipid consisted of a soybean oil emulsion that was high in
omega-6 polyunsaturated fatty acids (SO; 450 μl/day of a
20 % or 20 g/dL emulsion; Intralipid, Fresenius Kabi, Bad
Homburg, Germany), an 80 % olive oil and 20 % soybean
oil emulsion that was high in omega-9 monounsaturated
fatty acids (OOSO; 450 μl/day of a 20 % or 20 g/dL emul-
sion; ClinOleic, Baxter Healthcare, Deerfield, Illinois), a
macadamia nut oil emulsion that was high in omega-7
and omega-9 monounsaturated fatty acids (MNO; 450 μl/
day of a 20 % or 20 g/dL emulsion; Baxter Healthcare,
Deerfield, Illinois), and a fish oil emulsion high in omega-
3 polyunsaturated fatty acids (FO; 900 μl/day of a
10 % or 10 g/dL emulsion; Omegaven, Fresenius Kabi,
Bad Homburg, Germany). The FO emulsion was only
available as a 10 % lipid emulsion while the other three
emulsions were available as 20 % emulsions. All lipid
emulsions contained 1.2 g/dL of egg yolk phospholipids.
Body weight was recorded daily. Blood (for plasma) and
liver tissues were collected at the end of the study and
stored at −80 °C until analyzed. The protocol for these
studies was approved (protocol # 2010-17) by the Method-
ist Research Institute’s Animal Research Committee (Ani-
mal Welfare Assurance Number-A3772-010) and strictly
followed the Guide for the Care and Use of Laboratory
Animals (NIH publication No.85-23, revised 1996).
Fatty acid analysis
Lipid emulsions (20 μL each) did not require fatty acid
extraction prior to analysis; therefore, these samples were
directly transmethylated in conjunction with an internal
standard (tricosanoic acid). Methanol-benzene 4:1 and
acetyl chloride were added to the samples while on dry
ice. The samples were placed in tubes, purged with
nitrogen gas, and subjected to methanolysis at room
temperature for 24 h. The reaction was stopped and
neutralized with K2CO3. Layers were separated by
centrifugation and an aliquot of the benzene layer was re-
moved for gas chromatography analysis [29]. For liver
analysis of fatty acids, a small sample (approximately
200 mg) was removed from an −80 °C freezer, thawed on
ice, and homogenized in cold PBS. An internal standard of
tricosanoic acid was added to the homogenates and
methanol:benzene (4:1; v:v) added. Acetyl chloride was
added while on dry ice, the samples sealed, transferred to
room temperature, and maintained until the reaction mix-
ture was melted. Transmethylation was performed as de-
scribed above. Fatty acid extraction of the mouse plasma
(100 μL) prior to analysis was not required; therefore, dir-
ect transmethylation of these samples were performed as
described above.
For gas chromatography analysis of fatty acids, the
benzene layer was recovered following centrifugation
and fatty acids were separated on a gas chromatography
system (Shimadzu GC2010) equipped with a Zebron
ZB-WAX plus column (100 m, 0.25 mm ID, 0.25 μm
film thickness) as described previously [29]. The oven
temperature was programmed from 30 °C (2 min hold)
to 180 °C @ 20 °C/min (2 min hold), then to 207 °C @
4 °C/min (3 min hold), then to 220 °C @ 2 °C/min
(2 min hold), and finally to 240 °C @ 2 °C/min (2 min
hold). Detection was performed with a FID @ 250 °C to
resolve fatty acid peaks, which were identified using
authentic standards (Restek Corp., Bellefonte, PA). Data
were analyzed with Shimadzu's GC solutions software.
Data are presented either as mg or μg/volume or weight
of tissues.
Oil Red O staining for lipid droplets
The liver tissues, which were frozen in OCT compounds,
were cut into 5 μm sections using a cryostat (Leica
CM1900; Leica Microsystems, Bannockburn, IL, USA).
The sections were mounted on slides and allowed to dry
for 1-2 h. The sections were fixed with 10 % formalin for
10 min, and then the slides were rinsed with PBS (PH 7.4).
After air dry, the slides were placed in 85 % propylene
glycol for 2 min, and stained in 0.5 % Oil Red O solution
in propylene glycol for 30 min. The slides were transferred
to an 85 % propylene glycol solution for 1 min, rinsed
in distilled water for 2 changes, and processed for
hematoxylin counter staining.
Triglyceride levels in hepatic tissues
Analysis of triglyceride in liver tissues was performed
using a commercial kit (Cayman Chemicals, MI). Briefly
liver tissues (100-300 mg) were homogenized in 2 ml of
standard diluent containing a mixture of protease inhibi-
tor cocktail (Roach Diagnostics, IN). The samples were
centrifuged at 10,000 × g for 10 min at 4 °C and the
supernatant was used to determine triglycerides as per
manufacturer’s instructions.
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Calculation of fatty acid synthesis enzyme activity
The ratio of 16:0 to 18:2n-6 was used to calculate a de
novo lipogenesis (DNL) index [30, 31]. The ratio of 18:1n-
9/18:0 was used to calculate hepatic stearoyl- CoA-1
(delta-9) desaturase activity [23, 32]. The ratio of 18:0/16:0
was used to calculate elongase activity [33].
Statistical analysis
The data are reported as mean ± SD unless stated other-
wise. All comparisons are made by one-way ANOVA
with Tukey’s post hoc test using SPSS Statistics 20 soft-
ware except for individual fatty acid analyses. Fatty acids
analyses were done on the normalized data (not adjusted
for interdependence) using “R (version 1.15.1)” software
[34]. Means differences were compared using studentized
range with Tukey’s hsd (honestly significant difference).
All significant values are reported at P <0.05. Values with
different letters or symbols are significantly different from
each other.
Results
Fatty acid composition of lipid emulsions
We selected four different lipid emulsions for study
based on their content of n-3, n-6, n-7, and n-9 long-
chain fatty acids (Table 1). The SO emulsion contained
linoleic acid (n-6 polyunsaturated fatty acid) as the
major fatty acid, accounting for nearly 56 % of total fatty
acid content. The OOSO emulsion contained oleic acid
(n-9 monounsaturated fatty acid) as the major fatty acid
(approximately 59 % of the total fatty acid content). The
MNO emulsion contained approximately 74 % monoun-
saturated fatty acids, of which 21 % of total fatty acids
was the n-7 monounsaturated fatty acid palmitoleic acid
(C16:1n-7) and 52 % was the n-9 monounsaturated fatty
acid oleic acid (C18:1n-9). This oil is one of the highest
dietary sources of n-7 monounsaturated fatty acids. The
MNO lipid had the lowest amount of polyunsaturated
fatty acids, accounting for only 4 % of total fatty acids.
The FO emulsion contained approximately 50 % of fatty
acids as long-chain n-3 polyunsaturated fatty acids
with approximately a 1:1 eicosapentaenoic acid (EPA) to
docosahexaenoic acid (DHA) ratio. All lipid emulsions
contained similar amounts of saturated fatty acids, thus
accounting for approximately 15-17 % (mean values) of
total fatty acids. The lipid emulsions differed in the ratio
of polyunsaturated to saturated fatty acids and monoun-
saturated to saturated fatty acids. However, they had
similar unsaturated to saturated fatty acid ratios.
Body weights and food intake
The daily body weights of animals (mean ± SD) on the
study diets (i.e., starch, sucrose, and fructose) were not
significantly different from each other before (starch,
21.80 ± 0.77 g; sucrose, 21.38 ± 0.44 g; fructose, 21.62 ±
0.82 g) or after (starch, 22.26 ± 01.16 g; sucrose, 21.73 ±
0.70 g; fructose, 22.45 ± 0.92 g) lipid emulsion adminis-
tration (Fig. 1). None of the animals were considered
obese. We also recorded average food intake by animals
in each group, and there were no significant differences
in food intake (2.5-3.0 g/day) among the different dietary
groups and among oil emulsion treatments. Overall, the
Table 1 Fatty acid composition of lipid emulsions. Values
(mean ± SD) represent % of total fatty acids
n = 5 SO OOSO MNO FO
n=5 % % % %
14:0 0.04 ± 0.002 0.63 ± 0.002 4.28 ± 0.02
c16:0 11.03 ± 0.1 12.66 ± 0.03 9.03 ± 0.03 10.05 ± 0.18
16:1n-7 0.08 ± 0.001 0.98 ± 0.004 21.04 ± 0.04 7.92 ± 0.03
16:2n-4 1.20 ± 0.03
16:3n-4 1.58 ± 0.013
18:0 3.88 ± 0.03 3.56 ± 0.009 2.88 ± 0.02 2.24 ± 0.21
18:1n-9 20.72 ± 0.14 59.13 ± 0.79 53.23 ± 0.17 9.15 ± 0.13
18:1n-7 1.52 ± 0.03 2.20 ± 0.02 3.19 ± 0.13 2.43 ± 0.04
18:2n-6 55.61 ± 0.39 18.18 ± 0.02 3.25 ± 0.005 2.69 ± 0.007
18:3n-6 0.24 ± 0.006
18:3n-3 5.69 ± 0.04 2.10 ± 0.003 0.13 ± 0.002 0.96 ± 0.01
18:4n-3 4.03 ± 0.01
20:0 0.29 ± 0.002 0.34 ± 0.001 2.11 ± 0.005
20:1n-9 0.19 ± 004 0.21 ± 0.003 2.78 ± 0.05 0.85 ± 0.02
20:4n-6 0.18 ± 0.002 0.18 ± 0.001 0.19 ± 00.002 1.47 ± 0.03
20:4n-3 1.03 ± 0.004
20:5n-3 21.73 ± 0.03
22:0 0.35 ± 0.002 0.12 ± 0.001 0.70 ± 0.003
22:1n-9 0.33 ± 0.006
22:5n-6 0.467 ± 0.010
22:5n-3 2.12 ± 0.01
22:6n-3 0.14 ± 0.002 0.08 ± 0.004 0.04 ± 0.001 20.63 ± 0.20
Total 100 ± 0.73 100 ± 0.91 100 ± 0.359 100 ± 0.846
Total SFA 15.59 ± 0.13 16.68 ± 0.04 15.35 ± 0.08 17.02 ± 0.41
Total MUFA 22.51 ± 0.02 62.53 ± 0.85 80.57 ± 0.28 20.35 ± 0.21
n-7 1.60 ± 0.03 3.18 ± 0.03 24.23 ± 0.05 10.35 ± 0.07
n-9 20.19 ± 0.15 59.35 ± 0.82 56.34 ± 0.23 10.00 ± 0.15
Total PUFA 61.63 ± 0.44 20.54 ± 0.03 3.91 ± 0.01 57.12 ± 0.39
n-3 5.83 ± 0.04 2.18 ± 0.01 0.17 ± 0.003 49.47 ± 0.30
n-6 55.80 ± 0.40 18.36 ± 0.02 3.74 ± 0.01 4.87 ± 0.05
PUFA/SFA 4.0 1.2 0.25 3.4
MUFA/SFA 1.4 3.7 5.2 1.2
USAT/SFA 5.4 5.0 5.5 4.6
SO soybean oil (20 g/dl), OOSOolive oil/soybean oil (20 g/dl), MNO macadamia
nut oil (20 g/dl), FO fish oil (10 g/dl), PUFA polyunsaturated fatty acids,
MUFA monounsaturated fatty acids, SFA saturated fatty acids, USAT unsaturated
fatty acids
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animals maintained their body weight during the study,
and there were no significant differences among control
(no additional lipid) and lipid emulsion groups for each
diet. However, there was a trend for lower body weight
in the fish oil starch diet and macadamia fructose diet
groups.
Effect of diets and lipid emulsions on plasma fatty acid
composition in mice fed high carbohydrate diets
The sucrose diet increased saturated (16:0, 18:0) and
monounsaturated fatty acids (18:1n-7, 18:1n-9) in the
plasma (Table 2, Fig. 2) compared to the starch diet group
(control). The fructose diet did not significantly alter
plasma fatty acids compared to the starch diet group. The
SO, OOSO, and MNO lipids (Table 2) had little effect
upon plasma fatty acids. However, plasma n-3 polyunsat-
urated fatty acids were increased by FO. Total plasma fatty
acids were increased by all lipid emulsions in the starch
diet group (Fig. 2), decreased in the sucrose diet group,
and similar to the no added lipid control group in the
fructose diet group. Plasma saturated fatty acids were
decreased by all lipid emulsions in the sucrose group but
not in the fructose group (Fig. 2). Monounsaturated fatty
acids were decreased by all lipid emulsions in the sucrose
group, but only by SO and FO in the fructose group.
Effect of diets and lipid emulsions on hepatic fatty acid
composition in mice fed high carbohydrate diets
The sucrose diet increased total hepatic fatty acids by 57 %
over levels in starch control animals. The higher fat con-
tent resulted from increases in saturated (16:0) and mono-
unsaturated fatty acids (16:1n-7, 18:1n-7, 18:1n-9) (Table 3,
Fig. 3). Fructose increased total hepatic fatty acids by
133 % by increasing both saturated (16:0) and monoun-
saturated fatty acid levels (16:1n-7, 18:1n-7, 18:1n-9).
The effects of the lipid emulsions upon hepatic fatty
acid content in the starch group reflected the compos-
ition of the lipid emulsions (Table 3, Fig. 3). FO elevated
n-3 polyunsaturated fatty acids (20:5n-3, 22:6n-3) and
decreased monounsaturated fatty acids (16:1n-7, 18:1n-7,
18:1n-9). MNO increased monounsaturated fatty acids
(18:1n-9).
All four lipid emulsions decreased total, saturated, and
monounsaturated fatty acid concentrations in the sucrose
and fructose groups by comparable amounts. Fatty acid
levels were reduced to values found in the starch group
(Fig. 3). In addition, FO significantly increased n-3 polyun-
saturated fatty acids and SO maintained higher n-6 poly-
unsaturated fatty acid levels.
Effect of lipid emulsions on hepatic fat content in mice
fed high carbohydrate diets
We further explored fat accumulation in hepatic tissues
by assaying tissue samples for lipid droplet accumulation
(Oil Red O staining) and total triglyceride levels. Com-
pared to animals on the starch diet, there was increased
accumulation of lipid droplets in animals on the sucrose
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Fig. 1 Effects of study diets upon changes in body weight over
time. Mice in test groups were fed for 3 days with a low-fat diet
containing starch, sucrose, or fructose as the carbohydrate source.
The study lipids were provided in the form of a lipid emulsion and
fed to animals for days 3-8 of the study. The arrows indicate start of
lipid emulsion feeding. Values are mean ± SD of 5 animals in each
group. No statistical difference is found between emulsion treatments
in each group
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and fructose diets as evidenced by increased staining
(Fig. 4). Fructose induced a greater number of droplets
than sucrose. Treatment of animals receiving the starch
diet with SO or MNO resulted in lipid droplet accumu-
lation; the OOSO and FO diets induced minimal lipid
droplet accumulation. Administration of all four lipid
emulsions to mice receiving the sucrose and fructose
diets reduced lipid droplet formation. We further vali-
dated this data by measuring total triglyceride levels in
liver samples. Consistent with lipid droplet accumula-
tion, data shown in Fig. 5 indicate that the sucrose and
fructose diets resulted in increased triglyceride levels in
the liver compared to the starch diet group. Treatment
with lipid emulsions reduced sucrose- and fructose-
induced triglyceride accumulation to levels seen in the
starch diet group. The effect was independent of type of
lipid emulsion used.
Effect of diet and emulsion on lipid metabolism
Hepatic de novo lipogenesis, as assessed using the 16:0/
18:2 index, was increased significantly in both sucrose
(2.5-fold) and fructose (3.5-fold) diet control groups (Fig. 6).
Treatment with lipid emulsions significantly reduced the
sucrose and fructose induced lipogenesis indices to values
similar to those in the starch diet group. The effect was
independent of the lipid emulsion composition. Feeding
Table 2 Plasma fatty acids (mg/ml; mean ± SD) of animals fed high carbohydrate diets
Fatty acidsΔ Control (no added lipid) SO OOSO MNO FO
A. Starch diet
16:0 0.57 ± 0.07a 0.66 ± 0.07 0.67 ± 0.14 0.77 ± 0.09 0.62 ± 0.06
16:1n-7 0.15 ± 0.02a*† 0.17 ± 0.04* 0.21 ± 0.08* 0.22 ± 0.05* 0.11 ± 0.02†
18:0 0.17 ± 0.01a 0.19 ± 0.03 0.18 ± 0.02 0.23 ± 0.04 0.25 ± 0.08
18:1n-9 0.51 ± 0.02a*† 0.62 ± 0.10*† 0.71 ± 0.18*† 0.83 ± 0.15* 0.47 ± 0.02†
18:1n-7 0.12 ± 0.02a 0.13 ± 0.03 0.15 ± 0.05 0.17 ± 0.05 0.07 ± 0.01
18:2n-6 0.35 ± 0.05a*† 0.50 ± 0.05* 0.45 ± 0.06* 0.46 ± 0.08* 0.37 ± 0.02†
20:4n-6 0.19 ± 0.05a 0.28 ± 0.02 0.24 ± 0.02 0.30 ± 0.06 0.22 ± 0.05
20:5n-3 <0.01 <0.01 <0.01 <0.01 0.24 ± 0.03*
22:6n-3 0.09 ± 0.02a 0.13 ± 0.02 0.13 ± 0.02 0.12 ± 0.07 0.33 ± 0.09*
B. Sucrose diet
16:0 0.86 ± 0.05b 0.60 ± 0.09 0.62 ± 0.06 0.63 ± 0.11 0.53 ± 0.02
16:1n-7 0.21 ± 0.04a 0.16 ± 0.01 0.21 ± 0.02 0.21 ± 0.07 0.17 ± 0.03
18:0 0.24 ± 0.02b 0.22 ± 0.03 0.19 ± 0.02 0.21 ± 0.03 0.18 ± 0.01
18:1n-9 1.21 ± 0.23b 0.73 ± 0.13*,† 0.84 ± 0.12*,† 0.90 ± 0.13* 0.61 ± 0.10†
18:1n-7 0.24 ± 0.04b 0.18 ± 0.03 0.21 ± 0.04 0.22 ± 0.01 0.13 ± 0.03
18:2n-6 0.31 ± 0.04a† 0.41 ± 0.07* 0.41 ± 0.04* 0.36 ± 0.07*† 0.22 ± 0.03§
20:4n-6 0.22 ± 0.05a 0.28 ± 0.05 0.27 ± 0.04 0.29 ± 0.06 0.16 ± 0.02*
20:5n-3 <0.01 <0.01 <0.01 <0.01 0.16 ± 0.03*
22:6n-3 0.11 ± 0.02a 0.14 ± 0.02 0.13 ± 0.02 0.14 ± 0.02 0.24 ± 0.03*
C. Fructose diet
16:0 0.54 ± 0.32a 0.71 ± 0.09 0.79 ± 0.08 0.69 ± 0.40 0.74 ± 0.15
16:1n-7 0.12 ± 0.07a 0.17 ± 0.05 0.24 ± 0.05 0.22 ± 0.13 0.17 ± 0.03
18:0 0.19 ± 0.11a,b 0.27 ± 0.02 0.23 ± 0.01 0.20 ± 0.11 0.22 ± 0.04
18:1n-9 0.80 ± 0.47a,b 0.70 ± 0.11 0.97 ± 0.13 0.80 ± 0.45 0.78 ± 0.07
18:1n-7 0.15 ± 0.09a,b 0.16 ± 0.04 0.24 ± 0.03* 0.20 ± 0.12 0.02 ± 0.02†
18:2n-6 0.20 ± 0.12a 0.50 ± 0.12 0.42 ± 0.04 0.35 ± 0.21 0.27 ± 0.06
20:4n-6 0.18 ± 0.10a 0.33 ± 0.05 0.29 ± 0.04 0.21 ± 0.12 0.22 ± 0.06
20:5n-3 <0.01 <0.01 <0.01 <0.01 0.19 ± 0.05*
22:6n-3 0.08 ± 0.05a 0.16 ± 0.03 0.14 ± 0.01 0.12 ± 0.07 0.33 ± 0.09*
ΔFatty acids with levels greater than 1 % of total fatty acids. Different alphabets (a, b) represent a statistical difference at P <0.05 between carbohydrate diets
(no added lipids) whereas different symbols (*,†,§) represent a statistical difference between control and emulsion groups within each carbohydrate dietary group.
Groups with the same alphabet letters or symbols are not statistically different from each other
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sucrose and fructose also increased delta-9 desaturase
activity (approximately 3- to 4-fold) compared to animals
on the starch diet (Fig. 6). Treatment with MNO caused a
small but significant increase, whereas treatment with FO
caused a significant decrease in delta-9 desaturase activity
in livers from the starch fed diet group. Treatment of the
sucrose/fructose groups with all lipid emulsions decreased
delta-9 desaturase activity to levels found in the starch diet
group. Interestingly, sucrose and fructose caused a signifi-
cant reduction in elongase activity compared to that of
starch fed animals (Fig. 6). Treatment with FO caused a
significant increase in elongase activity in livers of starch
fed animals. Treatment of the sucrose and fructose diet
groups with lipid emulsion increased elongase activity to
values found in the starch diet animals.
Discussion
NAFLD represents a group of diseases that result from
increased fatty acid flux within the liver. The most com-
mon manifestation of NAFLD is hepatic steatosis. How-
ever, NAFLD may progress to NASH, cirrhosis, and liver
failure. NAFLD is associated with increased morbidity,
mortality, and medical costs [2, 4, 11, 12]. Treatment of
NAFLD is based upon weight reduction and exercise in
overweight patients and dietary modifications designed
to reduce hepatic fatty acid fluxes. However, scientific
evidence on which to base dietary recommendations to
reduce hepatic lipid are lacking. The aim of this study
was to evaluate the effects of different dietary fatty acid
mixtures upon the development of hepatic steatosis.
Effect of sucrose/fructose upon development of hepatic
steatosis
In this study, we evaluated the effects of different carbohy-
drate sources (i.e., starch, sucrose, and fructose) upon the
development of hepatic steatosis. Our findings that both
sugar diets (fructose and sucrose) significantly increased
hepatic lipid content (steatosis) above levels found in the
starch diet (control) group, with the fructose diet being
more potent than the sucrose diet, are consistent with
other studies [8, 19, 20, 23].
Effect of lipid mixtures upon development of hepatic
steatosis
We evaluated the effects of complex lipid mixtures (based
upon different dietary oils) that varied in their content of
n-3 and n-6 polyunsaturated fatty acids, n-7 and n-9
monounsaturated fatty acids, and the polyunsaturated/
saturated fatty acid ratio upon the development of su-
crose/fructose induced hepatic steatosis. The main find-
ing of the study is that different mixtures of unsaturated
fatty acids (i.e. oleic acid, palmitoleic acid, linoleic acid,
eicosapentaenoic acid, docosahexaenoic acid) similarly
inhibited the development of sucrose/fructose induced
hepatic steatosis. Neither the specific quantity of polyun-
saturated (i.e. linoleic acid, eicosapentaenoic acid, docosa-
hexaenoic acid) or monounsaturated fatty acids (i.e. oleic
acid, palmitoleic acid) nor the ratio of polyunsaturated to
saturated fatty acids (varying from 0.25 to 4.0) affected the
inhibitory results. Steatosis was also independent of
the n-6 polyunsaturated/n-3 polyunsaturated fatty acid
ratio of the lipid mixtures, and emulsions containing
predominantly n-3 polyunsaturated fatty acids (i.e. ei-
cosapentaenoic acid, docosahexaenoic acid), n-6 poly-
unsaturated fatty acids (i.e. linoleic acid), or n-7/n-9
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monounsaturated fatty acids (i.e. oleic acid, palmitoleic
acid) were equally effective at inhibiting steatosis.
However, the lipid mixtures all had similar unsaturated/
saturated fatty acid ratios (varying from 4.6 to 5.5). All of
the study lipid mixtures inhibited the development of
fructose/sucrose-induced hepatic steatosis, reducing levels
to those found in the starch control diet group. The lipid
emulsions had no effect on hepatic lipid content in the
starch control group. Thus, the inhibitory effect depended
upon induction of lipogenesis. It is important to note that
the lipid mixtures used in this study had high unsatur-
ated/saturated fatty acid ratios (an attribute of the oils
used to make the lipid emulsions). In addition, saturated
fatty acid content (predominantly palmitic acid and stearic
acid) was approximately 16 % across all the lipid emulsion
mixtures. It is unclear if lipid mixtures with lower unsatur-
ated to saturated fatty acid ratios or higher saturated fatty
acid contents would have similar effects.
Mechanisms for lipid induced inhibition of hepatic
steatosis
The increase in hepatic lipid content in the sucrose/fruc-
tose diet groups was in the form of triglycerides and
primarily reflected increases in saturated and monoun-
saturated fatty acids, consistent with increased hepatic
de novo lipogenesis. In addition, we found that the fruc-
tose/sucrose diets increased de novo lipogenesis activity
and delta-9 desaturase activity. Excess carbohydrate intakes,
Table 3 Hepatic fatty acids (μg/mg protein; mean ± SD) of animals fed high carbohydrate diets
Fatty acidsΔ Control (no added lipid) SO OOSO MNO FO
A. Starch diet
16:0 7.59 ± 0.73a 7.84 ± 1.06 6.64 ± 0.53 9.26 ± 0.99 6.80 ± 0.61
16:1n-7 1.53 ± 0.15a 1.53 ± 0.57 1.46 ± 0.30 2.26 ± 0.48 0.61 ± 0.37*
18:0 3.42 ± 0.16a 3.26 ± 0.14 2.80 ± 0.30 3.16 ± 0.14 4.43 ± 0.92
18:1n-9 5.91 ± 0.63a 6.68 ± 1.77 6.49 ± 1.06 10.58 ± 1.48* 3.65 ± 1.05†
18:1n-7 1.74 ± 0.41a 1.61 ± 0.46 1.60 ± 0.51 2.66 ± 0.48 0.70 ± 0.14*
18:2n-6 3.14 ± 0.09a 3.89 ± 0.88 3.27 ± 0.44 3.00 ± 0.64 3.28 ± 1.45
20:4n-6 3.50 ± 0.23a 3.62 ± 0.30 3.06 ± 0.47 3.22 ± 0.32 3.05 ± 0.60
20:5n-3 0.03 ± 0.02a 0.02 ± 0.02 0.01 ± 0.01 0.01 ± 0.02 1.23 ± 0.50*
22:6n-3 2.01 ± 0.13a 2.22 ± 0.24 1.84 ± 0.18 2.00 ± 0.29 4.38 ± 0.15*
B. Sucrose diet
16:0 12.06 ± 1.47b 7.25 ± 1.25 8.29 ± 1.56 8.06 ± 1.60 8.23 ± 0.81
16:1n-7 2.44 ± 0.41b 1.27 ± 0.23 1.99 ± 0.50 1.95 ± 0.57 1.70 ± 0.14
18:0 3.31 ± 0.61a 3.78 ± 0.36 3.87 ± 0.52 3.67 ± 0.17 4.02 ± 0.33
18:1n-9 17.34 ± 4.92b 8.98 ± 2.72* 10.22 ± 2.65* 11.26 ± 3.61* 8.30 ± 1.43*
18:1n-7 3.38 ± 0.29b 2.34 ± 0.76 2.82 ± 0.63 3.08 ± 0.38 1.92 ± 0.24
18:2n-6 2.03 ± 0.06b 3.32 ± 0.59 3.86 ± 0.72 3.17 ± 0.45 2.36 ± 0.42
20:4n-6 2.80 ± 0.19a 3.92 ± 0.37 4.15 ± 0.34 3.86 ± 0.28 2.68 ± 0.22
20:5n-3 0.01 ± 0.02a 0.03 ± 0.01 0.04 ± 0.02 0.02 ± 0.02 1.41 ± 0.21*
22:6n-3 1.55 ± 0.18a 2.07 ± 0.23* 2.46 ± 0.18* 2.25 ± 0.30* 3.93 ± 0.34†
C. Fructose diet
16:0 18.27 ± 4.35c 6.83 ± 1.20* 6.84 ± 1.95* 7.24 ± 1.20* 8.27 ± 0.50*
16:1n-7 3.30 ± 1.29b 1.08 ± 0.40* 1.38 ± 0.46* 1.58 ± 0.42* 1.36 ± 0.12*
18:0 4.24 ± 0.25a 3.59 ± 0.30 3.12 ± 0.48 3.06 ± 0.24 3.71 ± 0.33
18:1n-9 29.43 ± 5.86c 6.05 ± 1.15* 7.94 ± 1.32* 7.58 ± 2.17 8.10 ± 0.73*
18:1n-7 5.10 ± 1.25c 1.71 ± 0.53* 2.05 ± 0.51* 2.26 ± 0.41* 1.49 ± 0.29*
18:2n-6 2.03 ± 0.40b 3.23 ± 0.88 2.29 ± 0.61 2.49 ± 0.52* 1.90 ± 0.54
20:4n-6 2.68 ± 0.17a 3.51 ± 0.19 3.04 ± 0.59 2.92 ± 0.24 2.53 ± 0.29
20:5n-3 <0.01a 0.01 ± 0.02 0.01 ± 0.01 0.01 ± 0.01 1.17 ± 0.22*
22:6n-3 1.44 ± 0.21a 2.03 ± 0.33 1.59 ± 0.37 1.75 ± 0.27 3.95 ± 0.55*
ΔFatty acids with levels greater than 1 % of total fatty acids. Different alphabets represent a statistical difference at P <0.05 between diets (no added lipids)
whereas different symbols represent a statistical difference between emulsion groups within each dietary group
Siddiqui et al. Nutrition & Metabolism  (2015) 12:41 Page 8 of 14
particularly in the form of sucrose or fructose, are known
to stimulate de novo lipogenesis [8, 10, 17]. The increase in
lipogenesis found in this study is comparable to the in-
creased lipogenesis found in patients with NAFLD [10–12].
Thus, our study results suggest that the primary mechan-
ism for the lipid inhibitory effects upon steatosis relates to
inhibition of lipogenesis induced by the sugars. Total poly-
unsaturated fatty acid content of the liver was not altered
by the sucrose/fructose diets. Polyunsaturated fatty acids
reflect dietary intake (essential fatty acids) and adipose tis-
sue lipolysis (from stored dietary polyunsaturated fatty
acids), rather than de novo lipogenesis. The lack of effect of
the lipid emulsions upon liver lipid content in the starch
control group likely reflects the low level of hepatic lipid
and low lipogenesis activity in this group.
The stimulation of lipogenesis by high carbohydrate
intakes results from activation of transcription factors (i.e.
steroid responsive element binding protein 1c; SREBP1c)
and increased expression of lipogenic enzymes (i.e. fatty
acid synthase [FAS], stearoyl-CoA desaturase, acetyl-CoA
carboxylase [ACC], malic enzyme) [8, 10, 17]. In contrast
to carbohydrate, many fatty acids (i.e. n-3 and n-6 polyun-
saturated fatty acids) suppress lipogenesis by inhibiting
SREBP1c and transcription of genes involved in lipogen-
esis [23, 25–28]. Additionally, some fatty acids (i.e. n-3
polyunsaturated fatty acids) have been found to upregulate
expression of peroxisomal proliferator-activated receptor
alpha (PPARα) which increases fatty acid degradation
[13, 25]. Thus, fatty acids can increase fatty acid degrad-
ation and decrease fatty acid synthesis. The net result
would be decreased storage of lipids in tissues (i.e. less
hepatic steatosis).
Many studies have shown that both n-6 and n-3 polyun-
saturated fatty acids suppress lipogenesis and development
of hepatic steatosis [13, 23, 25–28, 35–37]. However, most
studies using dietary oils failed to directly compare n-6
with n-3 polyunsaturated fatty acids. Thus, it is difficult to
compare the potency of oils containing different quantities
of these polyunsaturated fatty acid mixtures. In contrast,
saturated fatty acids have been reported to have little in-
hibitory effects upon lipogenesis [13, 26–28, 36] and high
fat diets enriched with saturated fatty acids [23, 25, 38, 39]
have been reported to increase lipogenesis and hepatic
steatosis.
A limited number of studies have evaluated the effects
of monounsaturated fatty acids or oils containing high
monounsaturated fatty acids upon hepatic lipid metabol-
ism such as lipogenesis and hepatic steatosis. The effects
of olive oil upon hepatic steatosis have been variable with
reports of increased, decreased, or no effect upon steatosis
[40, 41]. The variability appears to depend upon the model
used, amount and type of olive oil, quality and compos-
ition of the olive oil, control group used for comparison,
and the fat/calorie content of the diets. Potential mecha-
nisms for decreased steatosis with olive oil include de-
creased hepatic expression of lipogenic genes through
inhibition of SREBP1c, increased hepatic fatty acid oxida-
tion through stimulation of PPARα, increased secretion of
very low density lipoproteins, anti-inflammatory effects,
and anti-oxidant actions [40, 41]. Our results using olive
oil are comparable to previous studies using different
animal models [40–43]. For example, Wani et al. [42]
induced hepatic steatosis in mice using a high fat diet
(42 % of energy as fat; over 16 weeks). Administration of
olive oil with the high fat diet decreased weight gain,
serum triglycerides, normalized liver enzyme levels, and
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decreased hepatic steatosis. Deng et al. [43] utilized
JCR:LA-cp rats (lack leptin receptors) to study hepatic
steatosis. Over 2 weeks, animals receiving 10 % of energy
as fat developed hepatic steatosis with induction of lipo-
genic enzymes. Rats fed diets enriched with olive oil (40 %
of energy) or menhaden oil (40 % of energy) demonstrated
reduced expression of SREBP-1c, reduced hepatic trigly-
ceride content, decreased lipogenesis (i.e. FAS, ACC), and
increased expression of enzymes mediating fatty acid oxi-
dation. In addition to the above studies with olive oil, oleic
acid and oleic acid rich diets have been shown to decrease
hepatic lipogenesis, expression of hepatic lipogenic genes
(SREBP1c, SREBP2, FAS, ACC), and expression of hepatic
pro-inflammatory genes (tumor necrosis factor alpha,
cyclooxygenase-2) [26, 44]. The olive oil-based lipid emul-
sion used in this study contains refined olive oil and does
not contain many of the phenolic compounds (i.e. phen-
olic alcohols, phenolic acids, flavonoids, lignans, secoir-
idoids) found in natural olive oil such as oleuropein,
tyrosol, or hydroxytyrosol. These phenolic compounds
have been shown to reduce hepatic steatosis [40, 45].
Saturated but not unsaturated fatty acids may induce
lipotoxicity [46–48], which could contribute to hepatic
damage during NAFLD. The effects of saturated fatty
acids may depend upon the presence of unsaturated fatty
acids. Monounsaturated fatty acids, added to saturated
Starch Diet Sucrose Diet Fructose Diet
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Fig. 4 Accumulation of lipid droplets in liver from animals receiving the starch, sucrose, and fructose diets. The liver tissue sections were first
stained with Oil Red O solution and then counter stained with hematoxylin. Controls received the low fat high carbohydrate diets with no added
lipid. Each picture (400x) is a representative of 5 liver sections from each group
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fatty acids, have been reported to attenuate cellular apop-
tosis and insulin resistance induced by saturated fatty
acids [21, 46, 48]. Toll-like receptors recognize saturated
fatty acids and may mediate many of their detrimental
effects upon tissues [4, 8]. These effects are inhibited by
unsaturated fatty acids. Thus, mixtures of different classes
of fatty acids may produce effects that differ from those of
the individual fatty acids and unsaturated fatty acids may
attenuate or block effects of saturated fatty acids.
Based upon the known effects of carbohydrates and fatty
acids upon lipogenesis/hepatic steatosis and the results of
this study, we hypothesize that lipid mixtures with high
unsaturated to saturated fatty acid ratios inhibited de novo
lipogenesis induced by sucrose/fructose. By suppressing
lipogenesis, the lipid mixtures inhibited development of
hepatic steatosis.
Other considerations
Different fatty acids, despite being structurally similar and
belonging to the same chemical class, may elicit different
biological effects [49]. Thus, generalizing fatty acid effects
by the degree of unsaturation, configuration of the double
bonds (i.e. cis or trans), length of the carbon chain, or
position of the double bonds (omega-3, omega-6, omega-
7, omega-9) may not predict physiological responses.
Poudyal et al. [49] has proposed classifying fatty acids
based upon biological activity (i.e. neutral, reduce risk
factors, increase risk factors, controversial evidence for
classification, inadequate research to allow classification).
Although such a system may be beneficial, biological ef-
fects vary with the model used, organ investigated, param-
eter measured, underlying illness or inflammatory state,
diet utilized, concomitant fatty acids, and many other vari-
ables. In addition, lipids used in studies may be complex
and contain variable amounts of different fatty acids. It is
difficult to classify fatty acids and complex fatty acid mix-
tures with a large number a different physiologic effects
using a single classification system. Despite lack of a
biological classification system, it is important not to
generalize the effects from one fatty acid to a class of
fatty acids. In this study, the predominant saturated fatty
acids of the lipid emulsions were palmitic acid and stearic
acid. The predominant unsaturated fatty acids varied with
the emulsion (Table 1). Soybean oil contained predomin-
antly linoleic acid (with lesser amounts of oleic acid), the
olive/soybean oil contained predominantly oleic acid (with
lesser amounts of linoleic acid), the macadamia nut oil
contained predominantly oleic acid (with lesser amounts
of palmitoleic acid), and the fish oil contained predomin-
antly eicosapentaenoic and docosahexaenoic acids. Oils
which vary significantly from the study lipids may not
produce similar effects.
Most studies of lipogenesis/steatosis utilized a single
carbohydrate diet based upon glucose or glucose/sucrose.
Few studies have utilized fructose, a common sweetener
implicated in the pathogenesis of NAFLD. We utilized
three carbohydrate diets (i.e. starch, sucrose, and fructose)
so that we could evaluate the interaction between carbo-
hydrate and lipid. It is important to use a starch based diet
as a control diet in order to determine the effects of lipids
upon normal carbohydrate intake. Most studies have eval-
uated a limited number of lipid formulations containing
high omega-3 or omega-6 polyunsaturated fatty acids or
evaluated single fatty acids or triglycerides containing one
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fatty acid. It is important to use dietary oils since these
represent the normal intake of lipids in the diet. There is
limited information related to monounsaturated fatty
acids and a lack of studies evaluating the effects of oils
containing high monounsaturated fatty acids. Many stud-
ies utilized very high saturated fatty acid diets, high fat
diets, or high calorie diets that are not representative of
normal intakes or utilized genetic or nutrient deficient
animal models of steatosis. Due to these concerns, we
used a normal mouse model, 3 different carbohydrate
diets (starch, sucrose, fructose), 4 different lipid formula-
tions derived from dietary oils, a eucaloric normal rodent
diet, and normal total and saturated fat intake. The
duration of this study is shorter than many published
studies of NAFLD. Importantly, the short duration of the
study was adequate for inducing hepatic steatosis and was
effective at demonstrating the steatosis inhibiting effects
of the various lipid mixtures. Thus, we believe that the
animal model utilized in this study represents a valid
model for studying NAFLD. Further studies are needed to
assess the efficacy of specified diets for prevention and
treatment of NAFLD. These studies should evaluate
interactions between dietary components such as carbohy-
drates and fats. Future studies should evaluate lipid
mixtures with different unsaturated/saturated fatty acid
ratios, different levels of lipid and calorie intakes, and
potential molecular mechanisms for the effects (i.e. ex-
pression of fatty acid synthesis and degradative enzymes
and transcription factors, proinflammatory mediators,
antioxidant systems).
Conclusion
In conclusion, this study indicates that both carbohydrate
source and lipid intake are important dietary components
modulating the development of hepatic steatosis. Simple
sugars (fructose > sucrose) are more potent for induction
of steatosis than complex carbohydrates. Moderate intake
of complex lipids with high unsaturated to saturated fatty
acid ratios can inhibit the development of high sucrose/
fructose-induced hepatic steatosis. We found no differ-
ence in the inhibitory effects of complex lipid formula-
tions based upon polyunsaturated fatty acid (n-3 or n-6)
or monounsaturated fatty acid (n-7 or n-9) content. Our
results suggest that the total unsaturated fatty acid content
is more important than the polyunsaturated fatty acid
content of formulations for inhibition of steatosis.
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